Move over gold: Could ASX 200 healthcare shares be the new 'safe-haven' investments?

Why healthcare shares have been healthier for the portfolio than gold miners.

| More on:
Health workers shake hands and congratulate each other on good news.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

When markets turn sour, investors tend to flock towards 'safe-haven' assets in an attempt to preserve wealth. In the past, gold has been the go-to during these times of instability.

Yet, if the past year has been anything to go by, perhaps healthcare shares included in the S&P/ASX 200 Index (ASX: XJO) are the new 'gold standard'.

Seeking out healthier returns than the ASX 200

Historically, the eye-catching yellow metal has delivered superior returns throughout periods of high inflation.

According to a recent article from Australian Resources and Investment, the price of gold rose an average of 14% when inflation was above 3%. Similarly, the precious metal achieved returns of almost 25% (on average) during bouts of inflation averaging above 5%.

That would lead investors to believe that gold exposure would be ideal amid the highest annual inflation we have seen in decades.

However, the price of gold per ounce has moved nearly 7% downward compared to a year ago.

Furthermore, the lack of protection extends over to ASX-listed gold mining shares. Even the biggest of the big have suffered tremendously in the last 12 months.

As shown below, the likes of Northern Star Resources Ltd (ASX: NST), Newcrest Mining Ltd (ASX: NCM), and Evolution Mining Ltd (ASX: EVN) have cratered 28.5%, 37.8%, and 55.6%, respectively. Whereas, a handful of ASX 200 healthcare shares have managed to hold up better and, in some cases, outperform.

TradingView Chart

While the returns might still be negative, the point is the reduced downside. Investments in Cochlear Limited (ASX: COH), ResMed Inc (ASX: RMD), and CSL Limited (ASX: CSL) have resulted in more modest falls of 18.6%, 6.3%, and 2.8%, respectively.

Yesterday, Janus Henderson portfolio manager Andy Acker highlighted some attractive traits of healthcare companies.

With interest rates expected to keep rising and economic growth potentially slowing, the pricing power and non-cyclicality of areas such as pharmaceuticals and managed care could continue to stand out.

Is there still value in gold as a hedge?

Despite the lacklustre performance of gold and gold mining shares, could there still be a case for holding these 'traditionally' inflation-hedged assets?

Firstly, the precious metal may have yielded a negative return in the last year. However, as demonstrated in the chart below, it has still outperformed the ASX 200 index. That alone could be justification that gold still has its protective properties.

TradingView Chart

For now, investors of gold mining shares will be hoping their luck soon turns. These companies are currently struggling with a double whammy. Simultaneously, gold prices are falling while input costs — such as labour and materials — are increasing.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 3 April 2025

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd., Cochlear Ltd., and ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this fund manager is all in on Pro Medicus shares and recently increased his bet

This high-flying stock has suffered from turbulence.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Why I'm taking a closer look at ResMed shares

The ResMed share price hasn’t escaped recent market volatility. Is it time to buy?

Read more »

Health professional working on his laptop.
Healthcare Shares

Trump 2.0: Macquarie's take on the winners and losers in Australian healthcare

Let's see what the broker is saying about these healthcare stocks.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Own CSL shares? You're getting a dividend paycheque today

There's a silver lining to today's sell-off.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

How this Trump appointee could pressure the CSL share price

A leading expert believes Donald Trump isn’t doing CSL shareholders any favours.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Top broker says Mesoblast shares can rocket 100%

Big returns could be on offer from this biotech according to Bell Potter.

Read more »

A man with a wide, eager smile on his face holds up three fingers.
Healthcare Shares

Forget Trump! Here are 3 reasons to buy this $32 billion ASX 200 healthcare share today

A leading expert forecasts more growth ahead for this $32 billion ASX 200 healthcare company.

Read more »

A scientist examining test results.
Healthcare Shares

1 ASX dividend stock down 43% I'd buy right now

This business could provide both dividends and growing, defensive earnings.

Read more »